US Drug Recall Register
Class II · Moderate risk Terminated Initiated Dec 17, 2012 (14 years ago)

EXPAREL (bupivacaine liposome injectable suspension), 1.3%, 266 mg/20 mL (13.3 mg/mL)…

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Subpotent; bupivacaine

What was recalled

EXPAREL (bupivacaine liposome injectable suspension), 1.3%, 266 mg/20 mL (13.3 mg/mL) single use vials, INVESTIGATIONAL USE. For Infiltration Only. Not for any other route of administration. Manufactured by Paelra Pharmaceuticals. Inc., San Diego, California, USA

Recalling firm
Pacira Pharmaceuticals, Inc.
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-168-2013

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Bupivacaine recalls

See all